tbuckley/cabot-search huggingface dataset:
Abstract P5-13-12: Symptom burden, unmet need for assistance, and psychosocial adaptation among longer term breast cancer survivors
Authors: SC Palmer, AN Blauch, DA Pucci, LA Jacobs
Journal: Cancer Research (2017)

Abstract Introduction: Advances have improved survival among breast cancer (BC) patients and 89% can expect &amp;gt;5 year survival. The price for this survival, however, may be physical and psychosocial symptoms that persist many years into the survivorship trajectory. Unmet needs for symptom management and the relationships between unmet needs, symptom burden, and psychosocial adaptation remain unclear. We examined these relationships among longer term BC survivors. Method: Eligibility included non-metastatic BC survivors diagnosed &amp;gt; 3 years prior and attendance at a survivorship-focused appointment. Nineteen common symptoms of disease and treatment were evaluated and participants reported unmet need for assistance for each symptom they experienced. Psychosocial adaptation was assessed through the Hospital Anxiety and Depression Scale (HADS). Results: 103 primarily white (72%), middle aged (M=62.7 yrs) BC survivors were recruited. Participants were, on average, 11.4 yrs from diagnosis and most (78.2%) reported Stage I or II BC. Participants reported an average of 9.2 symptoms, most commonly fatigue (67%), joint pain (66%), weight gain (60%), decreased sexual drive (55%), and insomnia (52%). Participants reported an average of 2.8 unmet needs for assistance with symptoms, most commonly joint pain (29%), fatigue (25%), weight gain (23%), and difficulty with memory (21%). Overall levels of depressive (M=2.45) and anxiety (M=4.89) symptoms were low, and elevated depressive and anxiety symptoms were reported by 3% and 18% of the sample, respectively. Number of symptoms and anxiety were unrelated to any demographic, disease or treatment variables. Depressive symptoms and unmet needs were related younger age (p &amp;lt; .05) and depressive symptoms were further related to not having received radiotherapy (p &amp;lt; .05). Number of symptoms experienced and unmet needs were moderately related to both depressive (all r &amp;gt; 0.49, p &amp;lt; .001) and anxiety symptoms (all r &amp;gt; 0.31, p &amp;lt; .01). Conclusion: Among long term BC survivors symptoms are common, while unmet need and symptoms of anxiety and depression are more modest. However, both symptoms and unmet need are associated with symptoms of depression and anxiety and represent a potentially missed opportunity for improving outcomes among BC survivors. Citation Format: Palmer SC, Blauch AN, Pucci DA, Jacobs LA. Symptom burden, unmet need for assistance, and psychosocial adaptation among longer term breast cancer survivors [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-13-12.
Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes
Authors: Shuhei Kurosawa, Noriko Doki, Masahiro Suyama, Satoshi Sasajima, Aiko Igarashi, Iyo Mimura, Hidetoshi Morita, Yuki Fujioka, Hiroyoshi Nishikawa, Yutaka Shimazu, Wataru Suda, Masahira Hattori, Yuho Najima, Kazuhiko Kakihana, Hisashi Sakamaki, Kenya Honda, Kazuteru Ohashi
Journal: Blood (2016)
Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge
Authors: Thomas Pagliardini, Franck E. Nicolini, Stephane Giraudier, Philippe Rousselot, Gabriel Etienne, Françoise Huguet, Agnes Guerci-Bresler, Bruno R. Varet, Martine Escoffre, Stephane Morisset, Francois-Xavier Mahon, Laurence Legros
Journal: Blood (2016)
Lack of interaction between NEMO and SHARPIN impairs linear ubiquitination and NF-κB activation and leads to incontinentia pigmenti
Authors: Elodie Bal, Emmanuel Laplantine, Yamina Hamel, Virginie Dubosclard, Bertrand Boisson, Alessandra Pescatore, Capucine Picard, Smaïl Hadj-Rabia, Ghislaine Royer, Julie Steffann, Jean-Paul Bonnefont, Valeria M. Ursini, Pierre Vabres, Arnold Munnich, Jean-Laurent Casanova, Christine Bodemer, Robert Weil, Fabrice Agou, Asma Smahi
Journal: Journal of Allergy and Clinical Immunology (2017)
Recombinant Bispecific Monoclonal Antibody (bsMAb) Against CD20 and CD22 Active In Vitro and In Vivo Against B-Cell Lymphomas.
Authors: Zhengxing Qu, Thomas M. Cardillo, Victoria Shi, Diana L. Delaney, Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
Journal: Blood (2006)
Overexpression of Lipases Enables Specific Cytotoxicity by the Lipase Inhibitor Orlistat in Chronic Lymphocytic Leukemia Cells.
Authors: Christian P. Pallasch, Janine Schwamb, Alexandra Schulz, Svenja Debey, David Kofler, Joachim L. Schultze, Michael Hallek, Alfred Ultsch, Clemens M. Wendtner
Journal: Blood (2006)
Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM).
Authors: Rabab M. Gaafar, Adolfo G. Favaretto, Vanesa Gregorc, Francesco Grossi, Jacek Jassem, Andreas Polychronis, Paolo Bidoli, Marcello Tiseo, Mary E.R. O'Brien, Ryaz Shah, Paul Taylor, Silvia Novello, Alberto Muzio, Alessandra Bearz, Pawel Badurak, Laurent Greillier, Antonio Lambiase, Claudio Bordignon
Journal: Journal of Clinical Oncology (2015)

7501 Background: Currently, there are no standard options for MPM patients who failed a pemetrexed-based chemotherapy (CT). NGR-hTNF, a tumor-targeted antivascular agent, displays antitumor activity through a vessel normalization that improves intratumor CT uptake and T-cell infiltration. Methods: MPM patients who progressed on or after a front-line pemetrexed-based regimen, stratified for performance status (PS) and CT agent, were randomly assigned to receive weekly NGR-hTNF 0.8 μg/m2 (arm A; n = 200) or placebo (arm B; n = 200), both given with BIC (gemcitabine [G], vinorelbine [V], doxorubicin [D] or supportive care). Primary endpoint was overall survival (OS). Hypothesis testing: hazard ratio (HR) = 0.72, 1-β = 0.80, α = 0.05. Results: Baseline characteristics were balanced between arms (A vs B): median age (65 vs 67 years); men (76% vs 74%); PS ≥ 1 (72% vs 69%); nonepithelial histology (15% vs 19%); poor EORTC score (30% vs 23%); prior treatment-free interval (TFI) < median of 4.8 months (47% vs 53%). Investigator-selected CT (n = 381, 95%): G 55%, V 42%, D 3%. Patients completing six CT cycles: 41% vs 32% (p = 0.08). Most common grade 3/4 toxicity: neutropenia (17% vs 19%) and fatigue (5% vs 8%). After a median follow-up of 18.9 months, OS did not differ significantly between arms in ITT analysis (median 8.4 vs 7.9 months; HR = 0.94 p = 0.61). By predefined OS analyses, there was a significant interaction only between treatment group and TFI (p = 0.008). In 198 patients with TFI shorter than 4.8 months after first-line therapy, median OS for NGR-hTNF vs placebo was 9.0 vs 6.3 months and 1-year OS was 39% vs 23%, respectively (HR = 0.69 p = 0.02; stratified HR = 0.65 p = 0.01). By CT agent, median OS for NGR-hTNF plus G vs placebo plus G was 9.0 vs 6.2 months and for NGR-hTNF plus V vs placebo plus V was 9.7 vs 6.9 months. A significant treatment-by-TFI interaction was also observed for PFS (p = 0.009), with 6-month rates in the short TFI subset of 25% for NGR-hTNF and 12% for placebo (HR = 0.71 p = 0.03). Conclusions: Though the primary endpoint was not met, OS and PFS benefit reported with NGR-hTNF plus CT in patients with short TFI deserves a confirmatory first-line phase III trial. Clinical trial information: NCT01098266.
Meta-analysis of side effects (SEs) of aromatase inhibitors (AI) and of tamoxifen (TAM) in large randomized clinical trials (RCT)
Authors: L. A. Vakaet
Journal: Journal of Clinical Oncology (2007)

11015 Background: The published data from large RCTs for the endocrine adjuvant treatment of postmenopausal breast cancer patients (ATAC and BIG 1–98) have shown us the difference in SEs between an AI vs TAM. Observed SEs in these trials are the result of an effect of both drugs: e.g. AIs induce bone loss and lead to an increase in fracture risk whereas TAM reduces fracture risk. We did a meta- analysis of comparable SEs in ATAC and BIG and combined this information with a second meta-analysis comparing an AI vs nil and a third meta-analysis comparing TAM vs nil. Methods: A relative risk (RR) meta-analysis was done on published data of SEs comparing AI vs TAM (ATAC Lancet 2002; BIG 1–98 NEJM 2005). SEs studied were: (1) fracture risk; (2) ischemic cerebrovascular events; (3) hypercholesterolemia; (4) hot flushes; (5) venous thromboembolic events and (6) any musculoskeletal events. Data for the comparison of AI vs nil were taken from MA.17 (NEJM 2003) and the combined arm of ATAC (Lancet 2002). Data for the comparison of TAM vs nil were taken from the P1 (JNCI 1998) and IBIS 1 (Lancet 2002). The assumption of a fixed effects model was used unless significant heterogeneity (Cochran Q test) was found. Results: In the comparison of fractures (ATAC and BIG combined) there was a 50% increase in RR for fractures in the AI arm. Our second meta-analysis showed that half of this increase was due to an effect of the AI and (according to the third meta- analysis) about half was due to a decrease of the RR for fractures thanks to TAM. Significant differences in cerebrovascular, hypercholesterolemia and hot flushes related events were due to a TAM effect. Concerning musculoskeletal events, significant heterogeneity was found when comparing the effect of an AI in the presence or absence of TAM. When patients get TAM together with an AI (ATAC combined arm) there is no increase in musculoskeletal events compared to the TAM alone arm. When an AI was compared to nil (MA.17) a significant increase in events was observed. We hypothesize that this heterogeneity is due to an estrogenic effect of TAM. Conclusion: This RR analysis allowed us to dissect the SEs profile of an AI and of TAM. The results for musculoskeletal events generate a new biological hypothesis. No significant financial relationships to disclose.
Contents Vol. 79, 2010
Authors: Franz Caspar, P. Bech, Graeme J. Taylor, Felicity L. Bishop, Fiona Barlow, Jan Walker, Clare McDermott, George T. Lewith, Alexander Heinzel, Ralf Schäfer, Hans-Wilhelm Müller, Andre Schieffer, Ariane Ingenhag, Simon B. Eickhoff, Georg Northoff, Matthias Franz, Hubertus Hautzel, A. Lok, T.L.S. Visscher, M.W.J. Koeter, J. Assies, C.L.H. Bockting, W.M.M. Verschuren, A. Gill, A.H. Schene, Harald Baumeister, Gordon Parker, K.M.L. Huijbregts, H.W.J. van Marwijk, F.J. de Jong, B. Schreuders, A.T.F. Beekman, C.M. van der Feltz-Cornelis, William Y. Shi, Andrew G. Stewart, David L. Hare, Paola Rocca, Mario Aimetti, Michela Giugiario, Enrico Pigella, Federica Romano, Barbara Crivelli, Giuseppe Rocca, Filippo Bogetto, Jaap Lancee, Victor I. Spoormaker, Jan van den Bout, Marleen De Bolle, Jeffrey G. Johnson, Filip De Fruyt
Journal: Psychotherapy and Psychosomatics (2010)
Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution
Authors: Arig Ibrahim-Hashim, Mark Robertson-Tessi, Pedro M. Enriquez-Navas, Mehdi Damaghi, Yoganand Balagurunathan, Jonathan W. Wojtkowiak, Shonagh Russell, Kam Yoonseok, Mark C. Lloyd, Marilyn M. Bui, Joel S. Brown, Alexander R.A. Anderson, Robert J. Gillies, Robert A. Gatenby
Journal: Cancer Research (2017)

Abstract Ongoing intratumoral evolution is apparent in molecular variations among cancer cells from different regions of the same tumor, but genetic data alone provide little insight into environmental selection forces and cellular phenotypic adaptations that govern the underlying Darwinian dynamics. In three spontaneous murine cancers (prostate cancers in TRAMP and PTEN mice, pancreatic cancer in KPC mice), we identified two subpopulations with distinct niche construction adaptive strategies that remained stable in culture: (i) invasive cells that produce an acidic environment via upregulated aerobic glycolysis; and (ii) noninvasive cells that were angiogenic and metabolically near-normal. Darwinian interactions of these subpopulations were investigated in TRAMP prostate cancers. Computer simulations demonstrated invasive, acid-producing (C2) cells maintain a fitness advantage over noninvasive, angiogenic (C3) cells by promoting invasion and reducing efficacy of immune response. Immunohistochemical analysis of untreated tumors confirmed that C2 cells were invariably more abundant than C3 cells. However, the C2 adaptive strategy phenotype incurred a significant cost due to inefficient energy production (i.e., aerobic glycolysis) and depletion of resources for adaptations to an acidic environment. Mathematical model simulations predicted that small perturbations of the microenvironmental extracellular pH (pHe) could invert the cost/benefit ratio of the C2 strategy and select for C3 cells. In vivo, 200 mmol/L NaHCO3 added to the drinking water of 4-week-old TRAMP mice increased the intraprostatic pHe by 0.2 units and promoted proliferation of noninvasive C3 cells, which remained confined within the ducts so that primary cancer did not develop. A 0.2 pHe increase in established tumors increased the fraction of C3 cells and signficantly diminished growth of primary and metastatic tumors. In an experimental tumor construct, MCF7 and MDA-MB-231 breast cancer cells were coinjected into the mammary fat pad of SCID mice. C2-like MDA-MB-231 cells dominated in untreated animals, but C3-like MCF7 cells were selected and tumor growth slowed when intratumoral pHe was increased. Overall, our data support the use of mathematical modeling of intratumoral Darwinian interactions of environmental selection forces and cancer cell adaptive strategies. These models allow the tumor to be steered into a less invasive pathway through the application of small but selective biological force. Cancer Res; 77(9); 2242–54. ©2017 AACR.
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
Authors: G L Uy, M P Rettig, R M Stone, M Y Konopleva, M Andreeff, K McFarland, W Shannon, T R Fletcher, T Reineck, W Eades, K Stockerl-Goldstein, C N Abboud, M A Jacoby, P Westervelt, J F DiPersio
Journal: Blood Cancer Journal (2017)

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
David Oliver: Deflecting blame for the NHS crisis
Authors: David Oliver
Journal: BMJ (2017)

In February, the BBC's week long "NHS Health Check" depicted the current troubles on the NHS front line. 1 In a television interview the health secretary, Jeremy Hunt, responded to stories about patients stranded for months in hospital or for hours on trolleys in overcrowded emergency departments.Hunt asserted that such incidents were "completely unacceptable" with "no excuse," 2 but strangely omitted his own leadership responsibility.In charge for four years with a very hands-on management style, he was also a cabinet minister in governments that drove through Andrew Lansley's disastrous Health and Social Care Act, 3 cut funds available for social care, 4 and presided over a widening NHS funding gap.
The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML).
Authors: Olatoyosi M. Odenike, Serhan Alkan, Dorie Sher, John E. Godwin, Dezheng Huo, Matthew Myers, Stephen J. Brandt, Yanming Zhang, David H. Vesole, Richard A. Larson, Wendy Stock
Journal: Blood (2004)
MODELO PREDICTIVO DE RIESGO DE HEMORRAGIA DIFERIDA TRAS RESECCIÓN ENDOSCÓPICA MUCOSA DE LESIONES COLORRECTALES DE GRAN TAMAÑO. GRUPO ESPAÑOL DE REM DE LA SEED
Authors: E Albéniz Arbizu, M Fraile González, D Martínez Ares, P Alonso Aguirre, C Guarner Argente, CJ Gargallo Puyuelo, F Ramos Zabala, J Rodríguez Sánchez, F Múgica Aguinaga, O Nogales Rincón, E Redondo Cerezo, A Herreros De Tejada, MA Álvarez, S Soto Iglesias, M Rodríguez Téllez
Journal: Endoscopy (2015)

Introducción: La hemorragia diferida (HD) es la principal complicación tras la resección endoscópica mucosa (REM) colorrectal.
Increased Risks of Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Myelofibrosis (MF) among 24577 First-Degree Relatives of 11039 Patients with Chronic Myeloproliferative Disorders (MPD) in Sweden.
Authors: Ola Landgren, Lynn R. Goldin, Sigurdur Y. Kristinsson, Jan Samuelsson, Magnus Bjorkholm
Journal: Blood (2007)
Late Occuring Severe Autoimmune Hemolytic Anemia in a Liver Transplanted Child.
Authors: Hulya Ozsahin, Michela Schaeppi, Thierry Peyrard, Fabienne Gumy-Pause, Klara Posfay-Barbe, Christophe Chardot, Dominique Belli, Michèle Siegenthaler
Journal: Blood (2007)
CPX-351 Markedly Reduces Renal and Hepatic Clearance Rates for Cytarabine (Cyt) and Daunorubicin (Daun) in Rats with an Associated Decrease in Excretory and Metabolic Burden Despite Providing Dramatic Increases in Systemic Drug Exposure Compared to Conventional Cyt+Daun
Authors: Lawrence D Mayer, Jeffrey Fulton, Heasook Kim-Kang, Yijun Yi, Peter Wang, Paul Tardi, Xiaowei Xi, Dennis Heller
Journal: Blood (2014)
CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).
Authors: E. Gabriela Chiorean, Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, Jeffrey R. Infante, Venu Gopal Bathini, Tina Evans Wood, Paul N. Mainwaring, Robert T. Muldoon, Philip R. Clingan, Volker Kunzmann, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Amy Ko, Brian Lu
Journal: Journal of Clinical Oncology (2013)

4058^ Background: nab-P + G showed promising efficacy in a phase I/II study in MPC, and decreases in CA19-9 correlated with OS. In MPACT, patients (pts) who received nab-P + G vs G had improved median OS (8.5 vs 6.7 mo; HR 0.72; p = 0.000015), PFS (5.5 vs 3.7 mo; HR 0.69; p = 0.000024) and ORR (23% vs 7%; p = 1.1 × 10 −10 ). Here we present a prespecified exploratory analysis of CA19-9 from the MPACT trial. Methods: 861 previously untreated pts with MPC were randomized 1:1 to receive nab-P 125 mg/m 2 + G 1000 mg/m 2 days 1, 8, and 15 every 4 weeks or G alone 1000 mg/m 2 weekly for 7 weeks followed by a week of rest (cycle 1) and then days 1, 8, and 15 every 4 weeks (cycle ≥ 2). CA19-9 was evaluated at baseline and then every 8 weeks. OS comparisons at different CA19-9 criteria were performed by stratified Cox proportional hazards model (P by stratified log-rank test using randomization criteria). Results: 750 pts had an evaluable CA19-9 at baseline. More pts in the nab-P + G arm vs the G arm demonstrated a best CA19-9 decrease from baseline of ≥ 20% and ≥ 90% (61% vs 44% and 31% vs 14%, respectively; Table). At the first postbaseline assessment (week 8), greater proportions of pts in the nab-P + G arm vs the G arm had CA19-9 decreases of ≥ 20% and ≥ 90% (Table). At that time point, for pts with a decrease of ≥ 20% in CA19-9, nab-P + G demonstrated a significantly longer OS vs G. The risk reduction for pts with a ≥ 90% decrease was greater than in pts with a ≥ 20% decrease. In pts with an 8-week CA19-9 decrease &lt; 20%, median OS for nab-P + G vs G was 8.3 vs 8.0 mo (HR 0.92; p = 0.705). The relationship of CA19-9 kinetics with OS will also be examined. Conclusions: Higher proportions of pts in the nab-P + G arm had CA 19-9 responses of ≥ 20% and ≥ 90% vs the G arm. Pts who achieved a CA19-9 decrease at 8 weeks of ≥ 20% or ≥ 90% had significantly longer OS with nab-P + G than with G. Clinical trial information: NCT00844649. [Table: see text]
Abstract P4-03-14: Stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer
Authors: JP Reddy, RL Atkinson, RA Larson, JK Burks, D Smith, BG Debeb, B Ruffell, C Creighton, JM Reuben, S Krishnamurthy, WF Symmans, A Brewster, SJ Van Laere
Journal: Cancer Research (2017)

Abstract Introduction: We hypothesized that normal breast tissue in inflammatory breast cancer (IBC) patients contains intrinsic differences, including increased mammary stem cells and macrophage infiltration, which may promote the IBC phenotype. Materials and Methods: Normal breast tissue at least 5cm away from primary tumors were obtained from mastectomy specimens. This included an initial cohort of 8 IBC patients and 60 non-IBC patients followed by a validation cohort of 19 IBC patients and 25 non-IBC patients. Samples were immunostained for either CD44+CD49f+CD133/2+ stem cell markers or the CD68 macrophage marker and correlated with IBC status. Automated quantitation of positive cells was employed for the validation cohort. We also examined the association between IBC status and previously published tumorigenic stem cell and IBC tumor signatures in the validation cohort samples. Results: 8 of 8 IBC normal tissue samples expressed CD44+CD49f+CD133/2+ stem cell markers in the initial cohort as opposed to 0/60 non-IBC normal tissue samples (p=0.001). Similarly, the median number of CD44+CD49f+CD133/2+ cells was 25.7 in the IBC validation cohort as opposed to 14.2 in the non-IBC validation cohort (p=0.007). 7 of 8 IBC samples expressed CD68+ macrophages in initial cohort as opposed to 12/48 non-IBC samples (p=0.001). In the validation cohort the median number of CD68+ cells was 3.7 in the IBC cohort vs 1.0 in the non-IBC cohort (p=0.06). Normal tissue of IBC patients was positively associated with a tumorigenic stem cell signature (p=0.02) and with a 79-gene IBC gene signature (p&amp;lt;0.001). Conclusions: Normal tissue from IBC patients is enriched for both mammary stem cells and macrophages. Further, normal tissue of IBC patients has higher association with both a tumorigenic stem cell signature and IBC-specific tumor signature. Collectively, these data suggest that normal tissue from IBC patients is distinct from non-IBC normal tissue and may support the hypothesis that a primed normal breast contributes to the development of IBC symptoms upon oncogenic insult. Validation of these results in additional normal tissue in cancer-free women would better determine causality. Citation Format: Reddy JP, Atkinson RL, Larson RA, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton C, Reuben JM, Krishnamurthy S, Symmans WF, Brewster A, Van Laere SJ. Stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-03-14.
The Leukemic Stem Cell in Polycythemia Vera and Primary Myelofibrosis Is Distinct From the Initiating JAK2 V617F-Positive Hematopoiertic Stem Cell
Authors: Jonathan M. Gerber, Brownhilda Ngwang, Hao Zhang, Donna M. Williams, Ophelia Rogers, Richard J. Jones, Alison R. Moliterno, Jerry L. Spivak
Journal: Blood (2011)